Promoting global cardiovascular health: Ensuring access to essential cardiovascular medicines in low- and middle-income countries

Journal of the American College of Cardiology

Volumn 57, Issue 20, 2011, Pages 1980-1987

  Kishore, Sandeep P ^a   Vedanthan, Rajesh ^b   Fuster, Valentin ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

cardiovascular disease; essential medicines; global access; noncommunicable chronic disease

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIDOCAINE; NITRATE;

AWARENESS; CARDIOVASCULAR DISEASE; COST CONTROL; DATA BASE; DRUG COST; DRUG INDUSTRY; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEALTH EDUCATION; HEALTH INSURANCE; HEALTH PROMOTION; HUMAN; PATIENT ADVOCACY; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED NATIONS; WORLD HEALTH;

EID: 79955829270     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.12.029     Document Type: Review

References (50)

1. R.A. Nugent, and A.B. Feigl Scarce donor funding for non-communicable diseases: will it contribute to a health crisis? 2010 Center for Global Development Washington, DC http://www.cgdev.org/content/publications/detail/ 1424546 Accessed December 4, 2010
2. C. Mathers, D.M. Fat, J.T. Boerma World Health Organization The Global Burden of Disease: 2004 Update 2008 World Health Organization Geneva
3. V. Fuster, and B.B. Kelly Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health 2010 National Academies Press Washginton, DC
4. S. Mendis, K. Fukino, and A. Cameron The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries Bull World Health Organ 85 2007 279 288 (Pubitemid 46556727)
5. A. Cameron, M. Ewen, D. Ross-Degnan, D. Ball, and R. Laing Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Lancet 373 2009 240 249
6. World Health Organization Equitable access to essential medicines: a framework for collective action WHO Policy Perspectives on Medicines no. 8 2004 WHO Geneva
7. T.A. Gaziano, A. Bitton, S. Anand, S. Abrahams-Gessel, and A. Murphy Growing epidemic of coronary heart disease in low- and middle-income countries Curr Probl Cardiol 35 2010 72 115
8. A. Mahal, A. Karan, and M. Engelgau The Economic Implications of Non-Communicable Disease for India 2010 World Bank Washington DC
9. B. Schwartlander, I. Grubb, and J. Perriens The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world Lancet 368 2006 541 546 (Pubitemid 44177530)
10. M. Mbali The Treatment Action Campaign and the History or Rights-Based, Patient-Driven HIV/AIDS Activism in South Africa Research Report No. 29 Durban, South Africa: University of Kwazulu-Natal Centre for Civil Society http://www.ukzn.ac.za/ccs/files/RReport-29.pdf Accessed August 27, 2010
11. R. Elliott South Africa: Treatment Action Campaign steps up pressure Can HIV AIDS Policy Law Rev 8 2003 40 41
12. M.M. Reidenberg Essential medicines for the whole world Clin Pharmacol Ther 82 2007 500 503 (Pubitemid 47622536)
13. World Health Organization WHO Essential Medicines Program http://www.who.int/topics/essential-medicines/en/ Accessed February 25, 2010
14. J.D. Quick, H.V. Hogerzeil, G. Velasquez, and L. Rago Twenty-five years of essential medicines Bull World Health Organ 80 2002 913 914 (Pubitemid 35408266)
15. L. Levison, and R. Laing The hidden costs of essential medicines Essential Drugs Monitor 33 2003 20 21
16. M. Twagirumukiza, L. Annemans, J.G. Kips, E. Bienvenu, and L.M. Van Bortel Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines Trop Med Int Health 15 2010 350 361
17. C.E. Vialle-Valentin, D. Ross-Degnan, J. Ntaganira, and A.K. Wagner Medicines coverage and community-based health insurance in low-income countries Health Res Policy Syst 6 2008 11
18. World Health Organization The WHO Essential Medicines Library http://apps.who.int/emlib Accessed August 27, 2010
19. World Health Organization Prequalification Program http://www.who.int/ topics/prequalification/en/ Accessed August 27, 2010
20. Medecins Sans Frontieres Untangling the Web of Price Reductions: A Pricing Guide for Developing Countries 10th edition 2008 Medecins Sans Frontieres Campaign for Access to Essential Medicines Geneva
21. World Health Organization The Doha Declaration on the TRIPS Agreement and Public Health http://www.who.int/medicines/areas/policy/doha-declaration/en/ index.html Accessed August 27, 2009
22. C.M. Correa Implications of the Doha Declaration on the TRIPS Agreement and Public Health 2002 World Health Organization Geneva http://www.who.int/ medicines/areas/policy/WHO-EDM-PAR-2002.3.pdf Accessed August 27, 2009
23. News Story on Thai Compulsory Licensing Dispute, JanuaryApril 2007 Consumer Project on Technology website http://www.cptech.org/ip/health/c/ thailand/thainews-janapr07.html Accessed August 27, 2010
24. N. Wong-Anan New CLs in Thailand for generic version of Kaletra and Plavix January 25, 2007 Reuters
25. Health Action International Uganda Medicine Pricing Survey Report http://www.haiweb.org/medicineprices.surveys.php April 2004 Accessed March 27, 2010
26. A. Kotwani, M. Ewen, and D. Dey Prices & availability of common medicines at six sites in India using a standard methodology Indian J Med Res 125 2007 645 654 (Pubitemid 47180968)
27. Stop Stock Outs: Ensure Access to Essential Medicines for All website http://stopstockouts.org/ Accessed March 27, 2010
28. B. Waning, W. Kaplan, A.C. King, D.A. Lawrence, H.G. Leufkens, and M.P. Fox Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases Bull World Health Organ 87 2009 520 528
29. D. Henry, and J. Lexchin The pharmaceutical industry as a medicines provider Lancet 360 2002 1590 1595 (Pubitemid 35356378)
30. A. Johnson Drug firms see poorer nations as sales cure July 7, 2009 Wall Street Journal Online A1 http://online.wsj.com/article/SB124691259063602065.html Accessed March 26, 2010
31. R. Hill, and M. Chui The pharmerging future Pharmaceutical Executive 29 2009 pe1 pe8
32. Pfizer's new market: Venezuela's working poor [online video] July 6, 2009 Wall Street Journal Online http://online.wsj.com/video/pfizer-new-market- venezuela-working-poor/59541EC4-AA26-4B18-9842-89D9AF27376A.html Accessed August 27, 2010
33. Management Sciences for Health International Drug Price Indicator Guide 2009 2010 Management Sciences for Health Arlington, VA http://www.msh.org/ resource-center/international-drug-price-indicator-guide.cfm Accessed August 27, 2010
34. L.M. Niens, A. Cameron, E. Van de Poel, M. Ewen, W.B. Brouwer, and R. Laing Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world PLoS Med 7 2010 e1000333
35. D. Maiga, and B. Williams-Jones Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector Health Policy 97 2010 130 135
36. R. Sallouta, R. Ali, and A.N. Sijari Medicine prices, affordability, availability and component costs in Syria http://www.haiweb.org/medicineprices/ surveys/200312SY/survey-report.pdf 2003 Accessed September 8, 2010
37. Health Action International Measuring Medicine Prices, Availability, Affordability and Price Components 2nd edition 2009 World Health Organization Geneva http://apps.who.int/medicinedocs/index/assoc/s14868e/s14868e.pdf Accessed September 8, 2010
38. M. Olcay, R. Laing Commission on Intellectual Property Rights, Innovation and Public Health Pharmaceutical tariffs: what is their effect on prices, protection of local industry, and revenue generation 2005 World Health Organization Geneva http://www.who.int/medicines/technical-briefing/tbs/ TariffsOnEssentialMedicines.pdf Accessed February 25, 2010
39. European Commission Working document on developing countries' duties and taxes on essential medicines used in the treatment of the major communicable diseases 2003 European Commission Brussels http://trade.ec.europa.eu/doclib/ docs/2003/june/tradoc-113184.pdf Accessed February 25, 2010
40. General Agreement on Tariffs and Trade The text of the General Agreement on Tariffs and Trade. The general agreement 1986 World Trade Organization Geneva http://www.wto.org/english/docs-e/legal-e/gatt47-e.pdf Accessed February 25, 2010
41. General Agreement on Tariffs and Trade Pharmaceutical Tariff Elimination Agreement Geneva: World Trade Organization http://www.wto.org/gatt-docs/English/ SULPDF/91770009.pdf Accessed February 25, 2010
42. Health Action International Medicine prices, availability, affordability & price components: guidance on medicine pricing policy options http://www.haiweb.org/medicineprices/articles/index.html Accessed September 8, 2010
43. R. Panchagnula, S. Agrawal, and Y. Ashokraj Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective Methods Find Exp Clin Pharmacol 26 2004 703 721 (Pubitemid 40075859)
44. WHO Expert Committee on Specifications for Pharmaceutical Preparations WHO Technical Report Series 929, 39th Report 2005 World Health Organization Geneva http://whqlibdoc.who.int/trs/WHO-TRS-929-eng.pdf Accessed February 25, 2010
45. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
46. T.A. Gaziano, L.H. Opie, and M.C. Weinstein Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis Lancet 368 2006 679 686
47. A. Guglietta, and M. Guerrero Issues to consider in the pharmaceutical development of a cardiovascular polypill Nat Clin Pract Cardiovasc Med 6 2009 112 119
48. United Nations The Millennium Development Goals http://www.un.org/ millenniumgoals/global.shtml Accessed February 25, 2010
49. MDG Gap Task Force Millennium Development Goal 8: Strengthening the Global Partnership for Development in a Time of Crisis MDG Gap Task Force Report 2009 2009 United Nations New York, NY
50. World Health Organization Prevention and control of noncommunicable diseases: implementation of the global strategy Report by the Secretariat. Sixty-first World Health Assembly http://apps.who.int/gb/ebwha/pdf-files/EB126/ B126-12-en.pdf May 2008 Accessed February 25, 2010